STEMI resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 168: Line 168:
❑ [[Clopidogrel]] <br>
❑ [[Clopidogrel]] <br>
: If age ≤ 75 years
: If age ≤ 75 years
:❑
:❑ Loading dose 300 mg
:❑
:❑  
: If age > 75 years
: If age > 75 years
:❑
:❑ Loading dose 75 mg
:❑
:❑  
----
----
'''Administer anticoagulant therapy''' <br>
'''Administer anticoagulant therapy''' <br>
❑ [[UFH]] <br>
❑ [[UFH]] <br>
❑ [[Enoxaparin]] <br>
:❑ IV bolus of 60 units/kg (maximum 4000 units)
:❑ Then infusion of 12 units/kg/hour (maximum 1000 units)
:❑ Adjust the infusion for a aPTT of 50-70 sec for 48 hours or until revascularization
❑ [[Enoxaparin]] (for up to 8 days or until revascularization)<br>
: If age <75 years
:❑
:❑
: If age ≥75 years
:❑
:❑
: If creatinine clearance <30 mL/min
:❑
❑ [[Fondaparinux]]
❑ [[Fondaparinux]]
:❑
:❑
:❑
</div>}}
</div>}}
{{familytree/end}}
{{familytree/end}}

Revision as of 16:48, 6 March 2014


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Definition

ST elevation myocardial infarction (STEMI) is a syndrome defined by symptoms of myocardial ischemia associated with persistent ST elevation on ECG and elevated cardiac enzymes.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. STEMI is a life-threatening condition and must be treated as such irrespective of the causes.

Risk Factors

Management

Diagnostic Approach

Shown below is an algorithm summarizing the diagnostic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction[1]


 
 
 
 
 
Characterize the symptoms:

Chest pain

❑ Sudden onset
❑ Sensation of tightness, pressure, or squeezing
❑ Absence of physical exertion
❑ Duration> 20 minutes
❑ Radiation to the jaw or left arm
❑ No relief with medications
❑ No relief with rest
❑ Worse with time

Dyspnea
Nausea
Vomiting

Sweating
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obtain a detailed history:

❑ Age
❑ Previous MI
❑ Previous PCI or CABG
❑ Cardiac risk factors:

Hypertension
Diabetes
Hypercholesterolemia
Smoking
Obesity
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

❑ Measure the blood pressure
❑ Measure the heart rate
❑ Auscultate the heart searching for murmurs
❑ Search for signs of CHF

❑ Decreased air entry in the lungs
❑ Edema in the extremities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rule out life threatening alternative diagnoses:

Aortic dissection
Pulmonary embolism
Cardiac tamponade
Tension pneumothorax

Esophageal rupture
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order labs and tests:

EKG
❑ Biomarkers

❑ Troponin I
❑ CK-MB
Creatinine
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirm STEMI by the presence of the following:

❑ EKG changes

❑ ST elevation in at least 2 contiguous leads of 2 mm (0.2 mV) in men or 1.5 mm (0.15 mV) in women in leads V2–V3 and/or of 1 mm (0.1mV) in other contiguous chest leads or the limb leads
❑ ST depression in at least two precordial leads V1-V4 (suggestive of posterior myocardial infarction)
❑ ST depression in several leads plus ST elevation in lead aVR (suggestive of occlusion of the left main or proximal LAD artery)
❑ New LBBB

❑ Increase in troponin

 
 
 
 
 

Therapeutic Apporach

Shown below is an algorithm depicting the therapeutic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.[1]

 
 
 
 
Initial Treatment
❑ Administer 162 - 325 mg of aspirin

❑ Administer oxygen when saturation <90%

❑ 2-4 L/min via nasal cannula

❑ Administer beta-blockers (unless contraindicated)

Metoprolol IV, 5 mg every 5 min, up to 3 doses
Carvedilol IV, 6,25 mg, two times a day (titrate to heart rate)

❑ Administer sublingual nitroglycerin 0.4 mg every 5 minutes for a total of 3 doses
❑ Administer IV morphine if needed

❑ Initial dose 2-4 mg
❑ 2-8 mg every 5 to 15 minutes, as needed

❑ Administer 80 mg atorvastatin
❑ Monitor with a 12-lead EKG all the time

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Determine if PCI is available
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCI is available
 
 
 
PCI is not available
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary PCI within 90 minutes
 
Transfer for primary PCI
FMC to device time ≤ 120 min
 
Fibrinolytic therapy within 30 min
FMC to device ≥ 120 min
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirm that the patient has one of the following indications:

❑ Symptoms of ischemia <12 hours (Class I, level of evidence A)
❑ Symptoms of ischemia <12 hours and contraindications to fibrinolytics irrespective of time delay (Class I, level of evidence B)
Cardiogenic shock irrespective of time delay (Class I, level of evidence B)
Heart failure irrespective of time delay (Class I, level of evidence B)

❑ Ongoing ischemia 12-24 hours following onset (Class IIa, level of evidence B)
 
 
 
 
 
Confirm that the patient has one of the following indications:
❑ Symptoms of ischemia <12 hours (Class I, level of evidence A)
❑ Ongoing ischemia 12-24 hours following onset (Class IIa, level of evidence C)

Confirm that the patient has no contraindications for fibrinolytics

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Administer ONE of the following antiplatelet agents (before or at the time of PCI):
P2Y12 receptor inhibitors

Clopidogrel 600 mg
Ticagrelor 180 mg
Prasugrel 60 mg

❑ IV GP IIb/IIIa inhibitors

Abciximab
❑ Loading dose 0.25 mg/kg IV bolus
❑ Maintenance dose 0.125 mg/kg/min
Eptifibatide
❑ Loading dose 180 mcg/kg IV bolus
❑ Another 180 mcg/kg IV bolus after 10 minutes
❑ Maintenance dose 2 mcg/kg/min
❑ Decrease infusion by 50% if creatinine clearance <50 mL/min
❑ Avoid in hemodialysis patients
Tirofiban
❑ Loading dose 25 mcg/kg
❑ Maintenance dose 0.15 mcg/kg/min
❑ Decrease infusion by 50% if creatinine clearance <30 mL/min

Administer ONE of the following anticoagulant therapy:
UFH

❑ If GP IIb/IIIa receptor antagonist planned: 50- to 70-U/kg IV bolus
❑ If no GP IIb/IIIa receptor antagonist planned: 70- to 100-U/kg bolus

Bivalirudin

❑ 0.75-mg/kg IV bolus, then 1.75–mg/kg/h infusion
❑ Additional bolus of 0.3 mg/kg if needed
❑ Decrease infusion to 1 mg/kg/h when creatinine clearance <30 mL/min
 
 
 
 
 
Administer fibrinolytic therapy

Tenecteplase single IV bolus

❑ 30 mg for weight <60 kg
❑ 35 mg for weight 60-69 kg
❑ 40 mg for weight 70-79 kg
❑ 45 mg for weight 80-89 kg
❑ 50 mg for weight ≥60 kg

Reteplase 10 units IV boluses every 30 min
Alteplase

❑ Bolus 15 mg, infusion 0.75 mg/kg for 30 min (maximum 50 mg)
❑ Then 0.5 mg/kg (maximum 35 mg) over the next 60 min

Streptokinase 1.5 million units IV administered over 30-60 min


Administer a P12Y2 inhibitor
Clopidogrel

If age ≤ 75 years
❑ Loading dose 300 mg
If age > 75 years
❑ Loading dose 75 mg

Administer anticoagulant therapy
UFH

❑ IV bolus of 60 units/kg (maximum 4000 units)
❑ Then infusion of 12 units/kg/hour (maximum 1000 units)
❑ Adjust the infusion for a aPTT of 50-70 sec for 48 hours or until revascularization

Enoxaparin (for up to 8 days or until revascularization)

If age <75 years
If age ≥75 years
If creatinine clearance <30 mL/min

Fondaparinux

FMC: First medical contact; UFH: Unfractionated Heparin

Contraindications to Fibrinolytic Therapy

Shown below is a table summarizing the absolute and relative contraindications for fibrinolytic therapy among STEMI patients.

Absolute contraindications Relative contraindications
❑ Prior intracranial hemorrhage

❑ Ischemic stroke within the last 3 months (Unless within 4.5 hours)
❑ Structural cerebral vascular lesion
❑ Primary of metastatic intracranial malignancy
❑ Suspicion of aortic dissection
❑ Increased bleeding tendency or actibe bleeding
❑ Severe head or facial trauma within the last 3 months
❑ Intracranial or intraspinal surgery within the last 2 months
❑ Severe hypertension uncontrolled by emergency therapy
❑ Previous treatment with streptokinase within the last 6 months

❑ Oral anticoagulation therapy

❑ Pregnancy
❑ Active puptic ulcer
❑ Previous history of chronic severe hypertension that is poorly controlled
❑ Elevated blood pressure at presentation, such as SBP >180 mmHg or DBP >110mmHg
❑ Previous history of ischemic stroke
❑ Dementia
❑ Intracranial pathology that does not meet the absolute contraindications
CPR that lasted more than 10 min or that is traumatic
❑ Major surgery in the last 3 weeks
❑ Internal bleeding within the last 2-4 weeks
❑ Non compressible vascular punctures

Discharge Medication[2]

 
 
 
 
 
 
 
Post-PCI Patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For all patients
 
 
 
For patients with LVEF< 40%
 
For patients with AF or Flutter
 
For patients that where already on
ACE inhibitors and Beta-blockers and
have LVEF<40% or Diabetes or HF
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Give aspirin
❑ 165-325 mg/d for 1 month for BMS: for 3 months for sirolimus-eluting stent; 6 months for paclitaxel-eluting stent
❑ 75-162 mg/d indefinitely

❑ Give clopidogrel

❑ 75 mg/d for at least 12 months for DES
❑ 75 mg/d minimum 1 month up to 12 months for BMS
❑ Give beta-blockers
 
 
 
❑ AddACE inhibitor
❑ Give ARBs if intolerant to ACE inhibitor
 
❑ Give warfarin to achieve INR of 2.0-3.0
❑ In patients requiring warfarin, clopidogrel, and aspirin therapy, an INR of 2.0 to 2.5 is recommended with low dose aspirin (75 mg to 81 mg) and a 75 mg dose of clopidogrel.
❑ Monitor closely for bleeding
 
❑ Use aldosterone blockade
 

Do's

  • Administer reperfusion therapy for all patients presenting with STEMI within 12 hours of the beginning of the symptoms (Class I, level of evidence A).
  • Administer a loading dose followed by a maintenance dose of clopidogrel, ticagrelor or prasugrel (if PCI is planned) as initial treatment instead of aspirin among patients with gastrointestinal intolerance or hypersensitivity reaction to aspirin.
  • Administer sublingual nitroglycerin in patients with ischemic chest pain; however, administer IV nitroglycerin among patients with persistent chest pain after three sublingual nitroglycerins.[3]
  • Discontinue non-steroidal anti-inflamatory drugs immediately. [4] [5]
  • Initiate therapeutic hypothermia among comatose patients with STEMI (Class I, level of evidence B).
  • Consider bare-metal stent among STEMI patients with any of the following (Class I, level of evidence C):
    • High bleeding risk
    • Lack of compliance for a one year regimen of dual antiplatelet therapy
    • Surgery or invasive procedure within the next year
  • Achieve the following therapeutic activated clotting time when administering UFH:
    • 200 to 250 seconds with the concomitant administration of GPIIbIIIa inhibitor
    • 250 to 300 seconds (HemoTec device) without the concomitant administration of a GPIIbIIIa inhibitor
    • 300 to 350 seconds (Hemochron device) without the concomitant administration of a GPIIbIIIa inhibitor
  • Consider using a mechanical circulatory support among hemodynamically unstable patients with STEMI requiring an urgent CABG (Class IIa, level of evidence C)

Don'ts

  • Do not administer IV beta-blockers among patients with elevated risk for cardiogenic shock, signs of heart failure, low ouput state, prolonged PR interval more than 0.24 seconds, second or third degree block or asthma (Class I, level of evidence B).
  • Do not administer IV GP IIb/IIIa inhibitors to patients with low risk of ischemic events or at high risk of bleeding and who are already on aspirin and P2Y12 receptor inhibitors therapy.
  • Do not administer nitroglycerine to patients with systolic BP < 90 mm Hg or ≥ to 30 mm Hg below baseline, severe bradycardia (< 50 bpm), tachycardia (> 100 bpm), or suspected RV infarction.
  • Do not delay the time for reperfusion.
  • Do not administer prasugrel among patients with prior history of strokes or TIAs (Class III, Level of evidence B).
  • Do not administer abciximab for patients nor scheduled for PCI. [7]

References

  1. 1.0 1.1 O'Gara, Patrick T.; Kushner, Frederick G.; Ascheim, Deborah D.; Casey, Donald E.; Chung, Mina K.; de Lemos, James A.; Ettinger, Steven M.; Fang, James C.; Fesmire, Francis M.; Franklin, Barry A.; Granger, Christopher B.; Krumholz, Harlan M.; Linderbaum, Jane A.; Morrow, David A.; Newby, L. Kristin; Ornato, Joseph P.; Ou, Narith; Radford, Martha J.; Tamis-Holland, Jacqueline E.; Tommaso, Carl L.; Tracy, Cynthia M.; Woo, Y. Joseph; Zhao, David X. (2013). "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction". Journal of the American College of Cardiology. 61 (4): e78–e140. doi:10.1016/j.jacc.2012.11.019. ISSN 0735-1097.
  2. Antman EM, Hand M, Armstrong PW; et al. (2008). "2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee". Circulation. 117 (2): 296–329. doi:10.1161/CIRCULATIONAHA.107.188209. PMID 18071078. Unknown parameter |month= ignored (help)
  3. Kaplan K, Davison R, Parker M, Przybylek J, Teagarden JR, Lesch M (1983). "Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy". Am J Cardiol. 51 (5): 694–8. PMID 6402912.
  4. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM; et al. (2011). "Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis". BMJ. 342: c7086. doi:10.1136/bmj.c7086. PMC 3019238. PMID 21224324. Review in: Evid Based Med. 2011 Oct;16(5):142-3
  5. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abramson S, Arber N; et al. (2013). "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials". Lancet. 382 (9894): 769–79. doi:10.1016/S0140-6736(13)60900-9. PMC 3778977. PMID 23726390. Review in: Ann Intern Med. 2013 Oct 15;159(8):JC12
  6. Anderson HV (1995). "Intravenous thrombolysis in refractory unstable angina pectoris". Lancet. 346 (8983): 1113–4. PMID 7475596.
  7. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE; et al. (2012). "2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 60 (7): 645–81. doi:10.1016/j.jacc.2012.06.004. PMID 22809746.


Template:WikiDoc Sources